| pubmed-article:8474308 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8474308 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8474308 | lifeskim:mentions | umls-concept:C0027996 | lld:lifeskim |
| pubmed-article:8474308 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8474308 | lifeskim:mentions | umls-concept:C1704417 | lld:lifeskim |
| pubmed-article:8474308 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8474308 | pubmed:dateCreated | 1993-5-14 | lld:pubmed |
| pubmed-article:8474308 | pubmed:abstractText | Familial defective apolipoprotein B-100 (FDB) is a dominantly inherited disorder associated with hypercholesterolemia, in which an amino acid substitution in apolipoprotein B-100 results in low-density lipoprotein (LDL) particles that bind poorly to the LDL receptor and accumulate in plasma. Patients with FDB described to date have been heterozygous for this disorder, and their plasma contains both normal and defective-binding LDL particles. We have evaluated the hypocholesterolemic effects of nicotinic acid (3 g/d) in four patients with FDB, and compared the response to that of nine patients with heterozygous familial hypercholesterolemia (FH). Concentrations of LDL decreased by 24% in patients with FDB and by 14% in patients with FH. These results support the view that drugs which reduce LDL synthesis may be particularly effective in the treatment of patients with FDB. | lld:pubmed |
| pubmed-article:8474308 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8474308 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8474308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8474308 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8474308 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8474308 | pubmed:issn | 0026-0495 | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:RussellS JSJ | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:BaconSS | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:MahleyR WRW | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:IllingworthD... | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:WeisgraberK... | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:SchmidtE BEB | lld:pubmed |
| pubmed-article:8474308 | pubmed:author | pubmed-author:ThatcherS RSR | lld:pubmed |
| pubmed-article:8474308 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8474308 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:8474308 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8474308 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8474308 | pubmed:pagination | 137-9 | lld:pubmed |
| pubmed-article:8474308 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:meshHeading | pubmed-meshheading:8474308-... | lld:pubmed |
| pubmed-article:8474308 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8474308 | pubmed:articleTitle | Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. | lld:pubmed |
| pubmed-article:8474308 | pubmed:affiliation | Department of Medicine, Oregon Health Sciences University, Portland 97201-3098. | lld:pubmed |
| pubmed-article:8474308 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8474308 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8474308 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
